• Angiography is the cornerstone of coronary diagnostics, but it provides only an anatomical picture of the arteries.
• Important conditions — such as microvascular dysfunction, vasospasm, or endothelial disease — are invisible on an angiogram, meaning disease can be missed even when patients have significant symptoms.
• Physiological tools like FFR and CFR exist, but they are time-consuming, operator-dependent, and do not assess microvascular function.
• As a result, patients may be undertreated or undergo unnecessary surgery, and opportunities for tailored, more effective care are missed.

Coronary disease is not limited to large artery blockages. ~70% of patients undergoing PCI have no major coronary artery obstruction — a range of mechanisms contribute to symptoms and outcomes:

• ANOCA (Angina with No Obstructive Coronary Arteries): Patients present with angina symptoms despite “normal” angiograms, leading to frequent under- or misdiagnosis.
• Microvascular Dysfunction: Impaired function of small vessels, invisible to angiography, significantly contributes to symptoms and adverse events.
• Endothelial Dysfunction: An early marker of vascular disease, not detected by conventional tools, yet strongly linked to future cardiovascular risk.

Current diagnostic approaches can fail to capture these mechanisms, leaving clinicians to make critical treatment decisions on incomplete data.

• Cardiologists require a practical, reliable way to assess complete coronary physiology during PCI.
• A tool that measures both large-vessel and microvascular function in real time could transform how patients are diagnosed and treated.
• By simplifying complex measurements into a single system, the iKor microcatheter has the potential to enable more confident coronary intervention decisions and improved patient outcomes.